Zoetis, Inc. Stock Plummets to New 52-Week Low of $73.06

Zoetis, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology industry, has reached a new 52-week low of USD 73.06 as of June 29, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 59.04%, contrasting sharply with the S&P 500's gain of 20.53% during the same period. Despite this downturn, Zoetis maintains a robust market capitalization of USD 51,081 million and demonstrates high management efficiency, evidenced by a return on equity of 80.42%. The company has also shown a strong ability to service its debt, reflected in a low debt-to-EBITDA ratio of 1.22 times. Additionally, Zoetis has reported positive results for the last six consecutive quarters, with operating cash flow reaching a peak of USD 2,929 million. The stock's price-to-earnings ratio stands at 19.00, while the dividend yield is at 1.78%. Although the stock has faced challenges, it continues to exhibit healthy long-term growth potential, with net sales increasing at an annual rate of 8.16%.